200 related articles for article (PubMed ID: 38576037)
1. Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.
Go EB; Lee JH; Cho JH; Kwon NH; Choi JI; Kwon I
J Biol Eng; 2024 Apr; 18(1):23. PubMed ID: 38576037
[TBL] [Abstract][Full Text] [Related]
2. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
Yang B; Kwon I
Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
[TBL] [Abstract][Full Text] [Related]
3. Computation-Aided Design of Albumin Affibody-Inserted Antibody Fragment for the Prolonged Serum Half-Life.
Kwon NH; Lee JH; Kwon I
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145517
[TBL] [Abstract][Full Text] [Related]
4. Chemical Modification of Cysteine with 3-Arylpropriolonitrile Improves the In Vivo Stability of Albumin-Conjugated Urate Oxidase Therapeutic Protein.
Yang B; Kwon I
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680451
[TBL] [Abstract][Full Text] [Related]
5. Thermostable and Long-Circulating Albumin-Conjugated
Yang B; Kwon I
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452259
[TBL] [Abstract][Full Text] [Related]
6. AlbuCatcher for Long-Acting Therapeutics.
Rho JH; Lee JH; Kwon I
ACS Omega; 2024 May; 9(21):22990-23000. PubMed ID: 38826564
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
Yang B; Kim JC; Seong J; Tae G; Kwon I
Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
[TBL] [Abstract][Full Text] [Related]
8. Site-Specific Albumination as an Alternative to PEGylation for the Enhanced Serum Half-Life in Vivo.
Yang B; Lim SI; Kim JC; Tae G; Kwon I
Biomacromolecules; 2016 May; 17(5):1811-7. PubMed ID: 27050863
[TBL] [Abstract][Full Text] [Related]
9. Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1.
Park J; Bak M; Min K; Kim HW; Cho JH; Tae G; Kwon I
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33672039
[TBL] [Abstract][Full Text] [Related]
10. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
11. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.
Bak M; Park J; Min K; Cho J; Seong J; Hahn YS; Tae G; Kwon I
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32316169
[TBL] [Abstract][Full Text] [Related]
13. Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.
Lim SI; Hahn YS; Kwon I
J Control Release; 2015 Jun; 207():93-100. PubMed ID: 25862515
[TBL] [Abstract][Full Text] [Related]
14. Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.
Cho J; Lim SI; Yang BS; Hahn YS; Kwon I
Sci Rep; 2017 Dec; 7(1):18041. PubMed ID: 29269881
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.
Sokolova EA; Stremovskiy OA; Zdobnova TA; Balalaeva IV; Deyev SM
Acta Naturae; 2015; 7(4):93-6. PubMed ID: 26798495
[TBL] [Abstract][Full Text] [Related]
16. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.
Adams R; Griffin L; Compson JE; Jairaj M; Baker T; Ceska T; West S; Zaccheo O; Davé E; Lawson AD; Humphreys DP; Heywood S
MAbs; 2016 Oct; 8(7):1336-1346. PubMed ID: 27315033
[TBL] [Abstract][Full Text] [Related]
17. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
